You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
复星系股价续涨逾6%-12% 郭广昌指集团合作研发新冠疫苗有效性逾九成将提速国内落地
阿思达克 11-10 10:07
全球新冠肺炎确诊病例突破5,000万宗大关及累计死亡人数超过125万人之际, 美国药厂辉瑞(PFE.US)宣布与德国药厂BioNTech(BNTX.US)联手研发的疫苗取得重大进展,在第三阶段测试中期结果显示参与者在第二次注射疫苗後七天成功率超过九成,意味市民有望接种疫苗28天後便可防疫,形容是一项重大里程碑,消息刺激辉瑞及BioNTech昨晚股价分别急涨7.7%及近14%。

本港相关股复星医药(02196.HK)今早急涨高见39.5元,暂受制8月初所创52周高位41.6元,现造36.8元,续涨12.5%,成交急增至1,783万股,涉资6.65亿元。复星国际(00656.HK)高见10.82元,创四个月高,现造10.72元,续升6.3%,成交增至1,320万股,涉资1.4亿元。

内媒引述复星国际董事长郭广昌於微博指,复星新冠疫苗在全球研发合作夥伴BioNTech与辉瑞联手研发的mRNA疫苗有效性超90%,远超此前预期,是全球合作的胜利,标志着在这场面对新冠病毒的战争中已经看到了胜利的曙光。在复星新冠疫苗全球研发取得突破性进展之际,郭广昌强调,复星将继续与政府监管、审批部门密切沟通协同,希望根据全球研发的进展和数据分析的结果,在符合中国法规的前提下,推动复星新冠疫苗尽早在中国上市使用。据了解,复星旗下复星医药今年3月获BioNTech授权,在中国大陆及港澳台地区独家开发、注册、商业化基於其专有mRNA技术平台研发的、针对新型冠状病毒的复星新冠疫苗(暂定名「复必泰」),并於7月在国内启动临床试验。目前,复星正与监管部门沟通,力争尽快在国内启动BNT162b2的桥接临床试验。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account